Analysts Set Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target at $44.00

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been assigned a consensus rating of “Buy” from the twelve brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $44.00.

A number of analysts recently weighed in on the stock. Wedbush upped their price target on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, July 30th. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Finally, Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 target price for the company.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several large investors have recently modified their holdings of the stock. Arizona State Retirement System acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $260,000. Squarepoint Ops LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at approximately $303,000. Seven Fleet Capital Management LP acquired a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at approximately $7,398,000. Finally, Braidwell LP bought a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $42,146,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of NASDAQ DMRA opened at $22.41 on Friday. Damora Therapeutics, Inc. Common Stock has a one year low of $3.50 and a one year high of $38.33. The firm has a market capitalization of $1.38 billion, a P/E ratio of -6.65 and a beta of 1.46. The company’s fifty day moving average is $29.05 and its two-hundred day moving average is $26.50.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. On average, sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.